Armoring Tumor-Infiltrating Lymphocytes (TIL) with Membrane-Bound IL-15 Improves T-Cell Phenotype & Enhances Persistence in Melanoma
Time: 9:00 am
day: Post-Conference Day - Tackling Solid Tumors
Details:
- OBX-115 engineered TIL therapy utilizes the cytoDRiVE® platform to enable regulation of membrane-bound IL15 (mbIL15) using a drug-responsive domain (DRD), obviating the need for IL2 administration
- mbIL15 selectively expands CD8+ T-cells with no IL2-like toxicity and reduced exhaustion, while supporting antitumor activity and persistence, and can re-activate expansion of persistent antigen-experienced OBX-115 TIL
- OBX-115 TIL have produced a 50% response rate in a first-in-human study, including two complete responses, without any dose-limiting toxicities
